Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | tachykinin receptor 3 | Starlite/ChEMBL | References |
Species | Potential target | Known druggable target/s | Ortholog Group |
---|---|---|---|
Echinococcus multilocularis | tachykinin peptides receptor 99D | Get druggable targets OG5_131969 | All targets in OG5_131969 |
Echinococcus granulosus | tachykinin peptides receptor 99D | Get druggable targets OG5_131969 | All targets in OG5_131969 |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Schistosoma mansoni | hyperpolarization activated cyclic nucleotide-gated potassium channel | 0.0007 | 0.0005 | 0.0006 |
Schistosoma mansoni | cyclic-nucleotide-gated cation channel | 0.0007 | 0.0005 | 0.0006 |
Echinococcus multilocularis | tachykinin peptides receptor 99D | 0.036 | 0.119 | 0.1185 |
Loa Loa (eye worm) | hypothetical protein | 0.0011 | 0.0017 | 0.0091 |
Schistosoma mansoni | voltage-gated potassium channel | 0.0041 | 0.0119 | 0.0136 |
Echinococcus multilocularis | potassium voltage gated channel subfamily H | 0.0038 | 0.0107 | 0.0102 |
Schistosoma mansoni | voltage-gated potassium channel | 0.0007 | 0.0005 | 0.0006 |
Loa Loa (eye worm) | kinesin-like protein KLP2 | 0.0387 | 0.1282 | 1 |
Echinococcus multilocularis | potassium voltage gated channel subfamily H | 0.0011 | 0.0017 | 0.0012 |
Brugia malayi | Voltage-gated potassium channel, HERG (KCNH2)-related. C. elegans unc-103 ortholog | 0.0038 | 0.0107 | 0.0798 |
Echinococcus granulosus | voltage gated potassium channel | 0.0011 | 0.0017 | 0.0012 |
Brugia malayi | Kinesin motor domain containing protein | 0.0387 | 0.1282 | 1 |
Schistosoma mansoni | hyperpolarization activated cyclic nucleotide-gated potassium channel | 0.0007 | 0.0005 | 0.0006 |
Trichomonas vaginalis | voltage and ligand gated potassium channel, putative | 0.0035 | 0.0099 | 1 |
Schistosoma mansoni | cyclic-nucleotide-gated cation channel | 0.0007 | 0.0005 | 0.0006 |
Echinococcus multilocularis | voltage gated potassium channel | 0.0011 | 0.0017 | 0.0012 |
Plasmodium falciparum | kinesin-5 | 0.0387 | 0.1282 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0033 | 0.009 | 0.0666 |
Schistosoma mansoni | voltage-gated potassium channel | 0.0011 | 0.0017 | 0.0019 |
Schistosoma mansoni | voltage-gated potassium channel | 0.0011 | 0.0017 | 0.0019 |
Echinococcus multilocularis | kinesin family 1 | 0.2981 | 1 | 1 |
Schistosoma mansoni | cyclic-nucleotide-gated cation channel | 0.0007 | 0.0005 | 0.0006 |
Brugia malayi | Voltage-gated potassium channel, EAG (KCNH1)-related. C. elegans egl-2 ortholog | 0.0011 | 0.0017 | 0.0091 |
Echinococcus granulosus | tachykinin peptides receptor 99D | 0.036 | 0.119 | 0.1185 |
Trichomonas vaginalis | voltage and ligand gated potassium channel, putative | 0.0035 | 0.0099 | 1 |
Entamoeba histolytica | kinesin, putative | 0.0387 | 0.1282 | 0.5 |
Echinococcus granulosus | potassium voltage gated channel subfamily H | 0.0038 | 0.0107 | 0.0102 |
Echinococcus granulosus | potassium voltage gated channel subfamily H | 0.0011 | 0.0017 | 0.0012 |
Toxoplasma gondii | kinesin motor domain-containing protein | 0.0387 | 0.1282 | 0.5 |
Loa Loa (eye worm) | voltage and ligand gated potassium channel | 0.0038 | 0.0107 | 0.0798 |
Schistosoma mansoni | voltage-gated potassium channel | 0.0041 | 0.0119 | 0.0136 |
Schistosoma mansoni | hypothetical protein | 0.2594 | 0.8698 | 1 |
Plasmodium vivax | kinesin-5 | 0.0387 | 0.1282 | 0.5 |
Schistosoma mansoni | kinesin eg-5 | 0.0387 | 0.1282 | 0.1473 |
Giardia lamblia | Kinesin-5 | 0.0387 | 0.1282 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | = 33 nM | Displacement of [125I]neurokinin B from cloned human NK3 receptor expressed in CHO cells | ChEMBL. | 16950620 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.